The South America human papillomavirus (HPV) vaccine market is expected to grow from US$ 173.52 million in 2022 to US$ 239.53 million by 2028; it is estimated to grow at a CAGR of 5.5% from 2022 to 2028.
Companies are undertaking many research and development activities to introduce advanced HPV tests. For instance, in May 2021, BD, a leading medical technology company, launched the first CE-marked assay for HPV screening from at-home self-collected vaginal samples. This allows laboratories to process self-collected samples via a BD diluent tube. At-home collection of samples will help address the urgent public health challenge of reaching out to women who do not attend routine cervical cancer screening. Further, in September 2020, drug administrations across the region approved the expanded use of F. Hoffmann-La Roche Ltd, CINtec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). The CINtec PLUS Cytology test identifies the simultaneous presence of the two biomarkers - p16 and Ki-67 - in a single cell. This abnormality is associated with HPV infections that progress to pre-cancer or cancer if not treated. A positive result of these two biomarkers means the person taking the test is at a high risk of getting the disease. Such robust developments in HPV diagnostics tests are likely to reshape the market during the forecast period.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South America human papillomavirus (HPV) vaccine market . The South America human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
Companies are undertaking many research and development activities to introduce advanced HPV tests. For instance, in May 2021, BD, a leading medical technology company, launched the first CE-marked assay for HPV screening from at-home self-collected vaginal samples. This allows laboratories to process self-collected samples via a BD diluent tube. At-home collection of samples will help address the urgent public health challenge of reaching out to women who do not attend routine cervical cancer screening. Further, in September 2020, drug administrations across the region approved the expanded use of F. Hoffmann-La Roche Ltd, CINtec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). The CINtec PLUS Cytology test identifies the simultaneous presence of the two biomarkers - p16 and Ki-67 - in a single cell. This abnormality is associated with HPV infections that progress to pre-cancer or cancer if not treated. A positive result of these two biomarkers means the person taking the test is at a high risk of getting the disease. Such robust developments in HPV diagnostics tests are likely to reshape the market during the forecast period.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South America human papillomavirus (HPV) vaccine market . The South America human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
South America Human Papillomavirus (HPV) Vaccine Market Segmentation
The South America human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country.- Based on type, the South America human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment would dominate the market in 2022. In terms of dosage, the South America human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment would dominate the market in 2022.
- Based on age, the South America human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment would dominate the market in 2022. In terms of application, the South America human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment would dominate the market in 2022.
- Based on end user, the South America human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment would dominate the market in 2022.
- Based on country, the South America human papillomavirus (HPV) vaccine market has been categorized into Brazil, Argentina, Chile, Guatemala, Peru, Colombia, and the Rest of South America. Brazil would dominate the market in 2022.
Table of Contents
1. Introduction
3. Research Methodology
4. SAM Human Papillomavirus (HPV) Vaccine Market - Market Landscape
5. SAM Human Papillomavirus (HPV) Vaccine Market - Key Market Dynamics
6. Human Papillomavirus (HPV) Vaccine Market - SAM Analysis
7. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By Type
8. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By Dosage
9. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By Age
10. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By Application
11. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By End User
12. SAM Human Papillomavirus (HPV) Vaccine Market - Country Analysis
13. Industry Landscape
14. Company Profiles
15. Appendix
Companies Mentioned
- GlaxoSmithKline plc.
- Inovio Pharmaceuticals
- Merck & Co., Inc.
- R-Pharm
- Sanofi
- Serum Institute of India Pvt. Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 134 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 173.52 Million |
| Forecasted Market Value ( USD | $ 239.53 Million |
| Compound Annual Growth Rate | 5.5% |
| No. of Companies Mentioned | 6 |
